V
TARO

Veritable’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Veritable’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,039
Closed -$544K – 922
2022
Q2 		$544K Buy
+15,039
New +$573K 0.01% 518

Other funds holding TARO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Veritable's TARO Position: Q3 2022 in Review

Veritable sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2022, closing a stake of 15,039 shares — an estimated $544K sold.

Veritable first reported a position in TARO in Q2 2022 and held it in 1 quarter. The position peaked at $544K in Q2 2022. 71 funds tracked by Wall St. Rank hold TARO as of Q3 2022.

  • Veritable reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2022 after selling out during the quarter.
  • Veritable sold 15,039 Taro Pharmaceutical Industries Ltd. shares in Q3 2022, an estimated $544K.
  • Veritable first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2022 and held it in 1 quarter.
  • Veritable's Taro Pharmaceutical Industries Ltd. position peaked at $544K in Q2 2022.
  • 71 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.